Enliven Therapeutics, Inc.

Until the Company can generate a sufficient amount of revenue from the commercialization of its product candidates, the Company may seek to raise any necessary additional capital through equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, 7 distribution, licensing or other strategic arrangements with third parties, or from grants.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

On August 13, 2025, the Company filed an automatic shelf registration statement on Form S-3ASR (the Automatic Shelf Registration Statement ) with the Securities and Exchange Commission (the SEC ) that allows the Company to undertake an indeterminate amount of equity and debt offerings.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Interest and dividends on marketable securities are included in interest income.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

9 At each balance sheet date, the Company assesses available-for-sale debt securities in an unrealized loss position to determine whether the unrealized loss or any potential credit losses should be recognized in net income (loss).

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

If both criteria are met, the Company records the associated lease liability and corresponding right-of-use ("ROU") asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

(Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update, including highlights of pipeline progress.

SEC original ↗Enliven Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better.

SEC original ↗Enliven Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

All statements other than statements of historical facts contained in this quarterly report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, development plans, planned preclinical studies and clinical trials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The Company is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Until the Company can generate a sufficient amount of revenue from the commercialization of its product candidates, the Company may seek to raise any necessary additional capital through equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, 7 distribution, licensing or other strategic arrangements with third parties, or from grants.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties.

SEC original ↗Enliven Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

SEC original ↗Enliven Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Legal Proceedings 36 Item 1A.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Exhibits 101 SIGNATURES 102 i SPECIAL NOTE REGARDING FO RWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

These forward-looking statements speak only as of the date of this quarterly report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this quarterly report on Form 10-Q.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.

SEC original ↗Enliven Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026